PREDICTORS OF G-CSF PROPHYLAXIS IN THE FIRST CYCLE OF CHEMOTHERAPY FOR FEBRILE NEUTROPENIA IN PATIENTS WITH NON-HODGKIN'S LYMPHOMA

被引：0
|
作者：
Lugtenburg, P. [1 ]
Asubonteng, J. [2 ]
DeCosta, L. [3 ]
Szabo, Z. [4 ]
Page, J. H. [5 ]
Wetten, S. [3 ]
机构：
[1] Erasmus Mc Canc Inst, Rotterdam, Netherlands
[2] Univ Pittsburgh, Pittsburgh, PA USA
[3] Amgen Ltd, London, England
[4] Amgen Inc, Zug, Switzerland
[5] Amgen Inc, Thousand Oaks, CA USA
来源：
HAEMATOLOGICA | 2014年 / 99卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
P583
引用
收藏
页码：196 / 196
页数：1
相关论文
共 50 条
  • [21] Intensive chemotherapy (LNHIV-91 regimen) and G-CSF for HIV associated non-Hodgkin's lymphoma
    Oksenhendler, E
    Gerard, L
    Dubreuil, ML
    Levy, Y
    Matheron, S
    Cazals-Hatem, D
    Chevret, S
    Clauvel, JP
    LEUKEMIA & LYMPHOMA, 2000, 39 (1-2) : 87 - 95
  • [22] Intra-hospital survival of non-Hodgkin's lymphoma patients with febrile neutropenia
    Ouyang, Lamei
    Wang, Daofeng
    Fang, Yi
    Liu, Xiao
    Li, Huan
    Lou, Ning
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE, 2017, 10 (05): : 8648 - 8655
  • [23] G-CSF Administration in First Line Chemotherapy With ABVD for Hodgkin's Lymphoma in Adults
    Pantarotto, M.
    Moreira, C.
    Ferreira, M.
    Lombo, L.
    Pereira, D.
    Faria, J.
    Mariano, M.
    Faustino, I.
    Domingues, N.
    Mariz, J. M.
    EUROPEAN JOURNAL OF CANCER, 2011, 47 : S646 - S646
  • [24] G-CSF use in patients receiving first-line chemotherapy for non-Hodgkin's lymphoma (NHL) and granulocyte-colony stimulating factors (G-CSF) as observed in clinical practice in Italy
    Vitolo, Umberto
    Angrili, Francesco
    DeCosta, Lucy
    Wetten, Sally
    Federico, Massimo
    MEDICAL ONCOLOGY, 2016, 33 (12)
  • [25] G-CSF use in patients receiving first-line chemotherapy for non-Hodgkin’s lymphoma (NHL) and granulocyte-colony stimulating factors (G-CSF) as observed in clinical practice in Italy
    Umberto Vitolo
    Francesco Angrili
    Lucy DeCosta
    Sally Wetten
    Massimo Federico
    Medical Oncology, 2016, 33
  • [26] A predictive model for life-threatening neutropenia and febrile neutropenia after the first course of chop chemotherapy in patients with aggressive non-Hodgkin's lymphoma.
    Intragumtornchai, T
    Sutheesophon, J
    Sutcharitjan, P
    Swasdikul, D
    BLOOD, 1998, 92 (10) : 225B - 225B
  • [27] A probability/risk matrix of febrile neutropenia to select patients for G-CSF primary prophylaxis
    Ramchandani Vaswani, A.
    Faez, L.
    Selvi Miralles, M.
    Antonio-Rebollo, M.
    Font Puig, C.
    Espinosa Arranz, J.
    Biosca, M.
    Vicente Rubio, E.
    Jimenez Fonseca, P.
    Carmona-Bayonas, A.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S275 - S276
  • [28] Combination chemotherapy with mitoguazon, ifosfamide, MTX, etoposide (MIME) and G-CSF can efficiently mobilize PBPC in patients with Hodgkin’s and non-Hodgkin’s lymphoma
    E Aurlien
    H Holte
    A Pharo
    S Kvaløy
    E Jakobsen
    EB Smeland
    G Kvalheim
    Bone Marrow Transplantation, 1998, 21 : 873 - 878
  • [29] Risk of febrile neutropenia among patients with intermediate-grade non-Hodgkin's lymphoma receiving CHOP chemotherapy
    Lyman, GH
    Morrison, VA
    Dale, DC
    Crawford, J
    Delgado, DJ
    Fridman, M
    LEUKEMIA & LYMPHOMA, 2003, 44 (12) : 2069 - 2076
  • [30] Combination chemotherapy with mitoguazon, ifosfamide, MTX, etoposide (MIME) and G-CSF can efficiently mobilize PBPC in patients with Hodgkin's and non-Hodgkin's lymphoma
    Aurlien, E
    Holte, H
    Pharo, A
    Kvaloy, S
    Jakobsen, E
    Smeland, EB
    Kvalheim, G
    BONE MARROW TRANSPLANTATION, 1998, 21 (09) : 873 - 878
12345